@article{12131,
  abstract     = {Replication-incompetent adenoviral vectors have been extensively used as a platform for vaccine design, with at least four anti-COVID-19 vaccines authorized to date. These vaccines elicit neutralizing antibody responses directed against SARS-CoV-2 Spike protein and confer significant level of protection against SARS-CoV-2 infection. Immunization with adenovirus-vectored vaccines is known to be accompanied by the production of anti-vector antibodies, which may translate into reduced efficacy of booster or repeated rounds of revaccination. Here, we used blood samples from patients who received an adenovirus-based Gam-COVID-Vac vaccine to address the question of whether anti-vector antibodies may influence the magnitude of SARS-CoV-2-specific humoral response after booster vaccination. We observed that rAd26-based prime vaccination with Gam-COVID-Vac induced the development of Ad26-neutralizing antibodies, which persisted in circulation for at least 9 months. Our analysis further indicates that high pre-boost Ad26 neutralizing antibody titers do not appear to affect the humoral immunogenicity of the Gam-COVID-Vac boost. The titers of anti-SARS-CoV-2 RBD IgGs and antibodies, which neutralized both the wild type and the circulating variants of concern of SARS-CoV-2 such as Delta and Omicron, were independent of the pre-boost levels of Ad26-neutralizing antibodies. Thus, our results support the development of repeated immunization schedule with adenovirus-based COVID-19 vaccines.},
  author       = {Byazrova, Maria G. and Astakhova, Ekaterina A. and Minnegalieva, Aygul and Sukhova, Maria M. and Mikhailov, Artem A. and Prilipov, Alexey G. and Gorchakov, Andrey A. and Filatov, Alexander V.},
  issn         = {2059-0105},
  journal      = {npj Vaccines},
  keywords     = {Pharmacology (medical), Infectious Diseases, Pharmacology, Immunology, SARS-COV-2, COVID},
  publisher    = {Springer Nature},
  title        = {{Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination}},
  doi          = {10.1038/s41541-022-00566-x},
  volume       = {7},
  year         = {2022},
}